In this episode, hosts Britany and Seth unpack the prospective Murcia AF Project III (MAFP-III) cohort study, which investigates remnant cholesterol (RC) and LDL-C discordance as predictors of thromboembolic events in patients with atrial fibrillation on oral anticoagulation. They explain how RC reflects triglyceride-rich lipoproteins (VLDL/IDL), how RC is calculated from standard lipid panels (total cholesterol minus LDL-C minus HDL-C), and the main finding: elevated RC predicts higher thromboembolic risk particularly when LDL-C is low. Over an average follow-up of about 1.86 years, the study reports an adjusted hazard ratio of 1.82 (95% CI 1.03–3.23, p=0.039) for thromboembolic events in the low-LDL-C group, with a linear RC–risk relationship in this subgroup and no similar association for high LDL-C. The episode discusses clinical implications for risk stratification, measurement practicality, and study limitations (observational design, single-center cohort, adherence not fully addressed) and considers future directions for research and potential RC-targeted therapies.
View all episodes
By Pharmacy & Acute Care UniversityIn this episode, hosts Britany and Seth unpack the prospective Murcia AF Project III (MAFP-III) cohort study, which investigates remnant cholesterol (RC) and LDL-C discordance as predictors of thromboembolic events in patients with atrial fibrillation on oral anticoagulation. They explain how RC reflects triglyceride-rich lipoproteins (VLDL/IDL), how RC is calculated from standard lipid panels (total cholesterol minus LDL-C minus HDL-C), and the main finding: elevated RC predicts higher thromboembolic risk particularly when LDL-C is low. Over an average follow-up of about 1.86 years, the study reports an adjusted hazard ratio of 1.82 (95% CI 1.03–3.23, p=0.039) for thromboembolic events in the low-LDL-C group, with a linear RC–risk relationship in this subgroup and no similar association for high LDL-C. The episode discusses clinical implications for risk stratification, measurement practicality, and study limitations (observational design, single-center cohort, adherence not fully addressed) and considers future directions for research and potential RC-targeted therapies.